Dextromethorphan and guaifenesin use need to be monitored carefully in sufferers with "lousy metabolizer" CYP2D6 enzyme concentrations and patients that are sedated. This mixture medication provides a huge median toxic dose (TD50) to median successful dose (ED50) ratio (or therapeutic index) in these patients. We only use excellent, credible resources https://assumi-un-pirata-professi22109.isblog.net/a-review-of-dextromethorphan-dxm-for-sale-in-usa-47367652